74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Nevro Corp
Closed
SectorHealthcare
5.84
Overview
Share price change
24h
Min
5.84
Max
5.85
Income | -38M -53M |
|---|---|
Sales | 8.6M 106M |
EPS | -0.646 |
Profit margin | -50.319 |
Employees | 1,099 |
EBITDA | -38M -43M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +0.17% upside |
Next Earnings | 6 May 2025 |
|---|
Market Cap | 7.6M 224M |
|---|---|
Previous open | 5.84 |
Previous close | 5.84 |
News Sentiment
By Acuity
50%
50%
180 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
Nevro Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Nevro Corp Forecast
Price Target
By TipRanks
0.17% upside
12 Months Forecast
Average 5.85 USD 0.17%
High 5.85 USD
Low 5.85 USD
Based on 9 Wall Street analysts offering 12 month price targets forNevro Corp - Dist in the last 3 months.
Sentiment
By Acuity
180 / 386 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Nevro Corp
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
